Onkologie. 2022:16(4):216-221 | DOI: 10.36290/xon.2022.041

Trifluridine/tipiracil treatment in a patient with mucinous metastatic colorectal carcinoma

Jiří Švec^{1, 2}, Vladimír Kořínek², Renata Soumarová¹

¹ Onkologická klinika 3. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice Královské Vinohrady, Praha

² Oddělení buněčné a vývojové biologie, Ústav molekulární genetiky AV ČR, v. v. i., Praha

Systemic oncologic treatment of metastatic colorectal carcinoma is currently based on chemotherapy in combination with targeted therapy based on the presence of activating mutations in the EGFR-RAS-RAF pathway, regardless of the histological subgroup of the tumor. In this case report, we describe a patient with a mucinous variant of colorectal carcinoma who responded very well to trifluridine/tipiracil in the third-line treatment. We briefly review the basic features of this histologic subtype, which accounts for 5-15% of all cases, is characterized by high extracellular mucin production, and is associated with a poorer prognosis related to a lower response to chemotherapy. We also point to the early occurrence of neutropenia as a potential predictive marker in trifluridine/tipiracil treatment.

Keywords: colorectal cancer, mucinous, trifluridine/tipiracil, Lonsurf, neutropenia.

Accepted: August 22, 2022; Published: August 24, 2022  Show citation